Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Keros Therapeutics, Inc. KROS

Healthcare  —  Biotechnology
11.62 0.07 0.61% as of 25 Sep
Market cap
$229.0M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Keros Therapeutics, Inc. (KROS) Business Profile

Updated before January 2025

Company Overview

Keros Therapeutics, Inc. (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel treatments for hematological and musculoskeletal disorders. Founded in 2015 and headquartered in Lexington, Massachusetts, Keros leverages its expertise in the transforming growth factor-beta (TGF-β) superfamily of proteins to develop innovative therapies that address unmet medical needs. The company is led by a team of seasoned executives and scientists, including its President and CEO, Jasbir S. Seehra, Ph.D., who brings decades of experience in drug development and biotechnology leadership. Other key members of the leadership team include Marc D. Blaustein, Chief Operating Officer, and Percy Carter, Ph.D., Chief Scientific Officer.

Core Business Segments

Keros Therapeutics focuses on developing therapies targeting the TGF-β superfamily, which plays a critical role in regulating cellular processes such as growth, differentiation, and repair. The company’s pipeline is primarily centered around two key therapeutic areas:

1. Hematological Disorders

Keros is developing treatments for rare and severe blood disorders. Its lead product candidate, KER-050, is designed to treat anemia and thrombocytopenia in patients with myelodysplastic syndromes (MDS) and myelofibrosis (MF). KER-050 works by inhibiting specific TGF-β superfamily ligands to promote red blood cell and platelet production.

2. Musculoskeletal Disorders

In the musculoskeletal space, Keros is advancing KER-047, a small molecule inhibitor targeting activin receptor-like kinase-2 (ALK2). This therapy is being developed to treat conditions such as fibrodysplasia ossificans progressiva (FOP) and other disorders characterized by abnormal bone growth and remodeling.

Additionally, Keros is exploring other potential applications of its proprietary platform, including treatments for pulmonary and cardiovascular diseases.

Business Model

Keros Therapeutics operates as a research-driven biopharmaceutical company, focusing on early-stage drug discovery and clinical development. The company’s business model revolves around the following key components:

  • Proprietary Platform: Keros leverages its deep understanding of the TGF-β superfamily to develop targeted therapies that address specific disease pathways.
  • Clinical Development: The company invests heavily in clinical trials to validate the safety and efficacy of its product candidates.
  • Partnerships and Collaborations: While Keros primarily focuses on in-house development, it also seeks strategic partnerships to accelerate the commercialization of its therapies.
  • Revenue Generation: As a clinical-stage company, Keros does not yet generate revenue from product sales. Instead, it relies on funding from investors, grants, and potential licensing agreements.

Strategic Direction

Keros Therapeutics is committed to advancing its pipeline of innovative therapies to address unmet medical needs. The company’s strategic priorities include:

  • Pipeline Expansion: Keros aims to broaden its portfolio by exploring additional indications for its existing product candidates and developing new therapies targeting the TGF-β superfamily.
  • Clinical Milestones: The company is focused on advancing KER-050 and KER-047 through clinical trials, with the goal of achieving regulatory approvals and bringing these therapies to market.
  • Sustainability Goals: While not explicitly stated, Keros is likely to adopt sustainable practices in its operations, given the growing emphasis on environmental, social, and governance (ESG) factors in the biopharmaceutical industry.
  • Global Reach: Keros plans to expand its presence in international markets, leveraging partnerships and collaborations to reach a broader patient population.

Competitive Landscape

Keros Therapeutics operates in a highly competitive biopharmaceutical sector, facing competition from both established players and emerging startups. Key competitors include:

  • Acceleron Pharma: A leader in TGF-β superfamily research, recently acquired by Merck & Co.
  • Blueprint Medicines: Focused on precision therapies for rare diseases and cancers.
  • Regeneron Pharmaceuticals: Known for its expertise in monoclonal antibodies and innovative therapies.
  • Sarepta Therapeutics: Specializes in genetic medicine for rare diseases.

Despite the competition, Keros differentiates itself through its proprietary platform and focus on niche therapeutic areas with high unmet needs.

Risk Factors

Like any biopharmaceutical company, Keros Therapeutics faces several risks that could impact its operations and financial performance:

  • Clinical Trial Risks: The success of Keros’s product candidates depends on the outcomes of clinical trials, which are inherently uncertain and time-consuming.
  • Regulatory Challenges: Obtaining regulatory approvals for new therapies is a complex and rigorous process.
  • Market Dependence: As a clinical-stage company, Keros does not yet generate revenue from product sales, making it reliant on external funding.
  • Supply Chain Disruptions: The company’s operations could be affected by disruptions in the supply of raw materials or manufacturing processes.
  • Competitive Pressure: The biopharmaceutical industry is highly competitive, with rapid advancements in technology and science.

Recent Developments

Keros Therapeutics has made significant progress in advancing its pipeline and corporate strategy. Recent highlights include:

  • Clinical Trial Updates: The company has reported positive interim data from its Phase 2 clinical trials of KER-050 in patients with MDS and MF.
  • Pipeline Expansion: Keros is exploring additional indications for KER-047, including rare genetic disorders and other bone-related conditions.
  • Corporate Milestones: The company has strengthened its leadership team and expanded its research capabilities to support future growth.
  • Global Developments: The COVID-19 pandemic has underscored the importance of resilient supply chains and accelerated the adoption of digital technologies in clinical trials.

Investment Considerations

Investors considering Keros Therapeutics should weigh the following strengths and risks:

Strengths

  • Innovative Pipeline: Keros’s focus on the TGF-β superfamily positions it as a leader in developing targeted therapies for rare diseases.
  • Experienced Leadership: The company is led by a team of seasoned executives with a proven track record in drug development.
  • Strong Market Potential: Keros’s therapies address significant unmet medical needs, offering substantial growth opportunities.

Risks

  • Early-Stage Company: As a clinical-stage company, Keros has yet to generate revenue from product sales.
  • Regulatory and Clinical Risks: The success of Keros’s pipeline depends on the outcomes of clinical trials and regulatory approvals.
  • Market Competition: The biopharmaceutical industry is highly competitive, with rapid advancements in technology and science.

Conclusion

Keros Therapeutics, Inc. is a promising player in the biopharmaceutical industry, leveraging its expertise in the TGF-β superfamily to develop innovative therapies for hematological and musculoskeletal disorders. While the company faces significant risks as a clinical-stage entity, its strong pipeline, experienced leadership, and focus on unmet medical needs position it for long-term growth. As Keros advances its product candidates through clinical trials and explores new therapeutic areas, it has the potential to make a meaningful impact on patients’ lives and deliver value to investors.